US · Healthcare · Biotechnology
EPS came in at -0.09 against a street estimate of -0.07 — a miss of 28.6%.
Analysts rate Trevi Therapeutics Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $26.18.
| Fund | Stake |
|---|---|
| NEA Management Company, LLC | 9.31% |
| BlackRock Inc | 7.21% |
| Frazier Life Sciences Management, L.P. | 7.00% |
| FMR Inc | 5.66% |
| Wellington Management Company LLP | 3.65% |
| Vivo Capital, LLC | 3.59% |
| Vanguard Capital Management, LLC | 3.51% |
| Marshall Wace Asset Management Ltd | 2.79% |
| Document | Date |
|---|---|
| Charter / bylaws change · Q2 2026 | 2026-06-04 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Results announced · Q2 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-21 |
| Results announced · Q2 2026 | 2026-04-17 |
| Annual report FY2025 | 2026-03-17 |
| Results announced · Q1 2026 | 2026-03-17 |
| Quarterly report · Q3 2025 | 2025-11-13 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Trevi Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.